The Galleri test — which isn’t covered by insurance — doesn’t come cheap. At $949 a pop, it’s out of the price range of most ...
MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback